Literature DB >> 32675252

Tumor microbial diversity and compositional differences among women in Botswana with high-grade cervical dysplasia and cervical cancer.

Travis T Sims1, Greyson W G Biegert2, Doreen Ramogola-Masire3, Kebatshabile Ngoni4, Travis Solley2, Matthew S Ning2, Molly B El Alam2, Melissa Mezzari5, Joseph Petrosino5, Nicola M Zetola6, Kathleen M Schmeler7, Lauren E Colbert2, Ann H Klopp2, Surbhi Grover6.   

Abstract

INTRODUCTION: We characterized the cervical 16S rDNA microbiome of patients in Botswana with high-grade cervical dysplasia and locally advanced cervical cancer.
METHODS: This prospective study included 31 patients: 21 with dysplasia and 10 with cancer. The Shannon diversity index was used to evaluate alpha (intra-sample) diversity, while the UniFrac (weighted and unweighted) and Bray-Curtis distances were employed to evaluate beta (inter-sample) diversity. The relative abundance of microbial taxa was compared among samples using linear discriminant analysis effect size.
RESULTS: Alpha diversity was significantly higher in patients with cervical cancer than in patients with cervical dysplasia (P<0.05). Beta diversity also differed significantly (weighted UniFrac Bray-Curtis, P<0.01). Neither alpha diversity (P=0.8) nor beta diversity (P=0.19) varied by HIV status. The results of linear discriminant analysis effect size demonstrated that multiple taxa differed significantly between patients with cervical dysplasia vs cancer. Lachnospira bacteria (in the Clostridia class) were particularly enriched among cervical dysplasia patients, while Proteobacteria (members of the Firmicutes phyla and the Comamonadaceae family) were enriched in patients with cervical cancer. DISCUSSION: The results of our study suggest that differences exist in the diversity and composition of the cervical microbiota between patients with cervical dysplasia and patients with cervical cancer in Botswana. Additional studies are warranted to validate these findings and elucidate their clinical significance among women living in sub-Saharan Africa, as well as other regions of the world. © IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cervical cancer; cervix uteri; gynecology; uterine cervical neoplasms

Year:  2020        PMID: 32675252      PMCID: PMC7893836          DOI: 10.1136/ijgc-2020-001547

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  42 in total

Review 1.  The role of the vaginal microbiome in gynaecological cancer.

Authors:  M Champer; A M Wong; J Champer; I L Brito; P W Messer; J Y Hou; J D Wright
Journal:  BJOG       Date:  2017-04-12       Impact factor: 6.531

Review 2.  Does the vaginal microbiota play a role in the development of cervical cancer?

Authors:  Maria Kyrgiou; Anita Mitra; Anna-Barbara Moscicki
Journal:  Transl Res       Date:  2016-07-15       Impact factor: 7.012

3.  Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21.

Authors:  Yongzhi Yang; Wenhao Weng; Junjie Peng; Leiming Hong; Lei Yang; Yuji Toiyama; Renyuan Gao; Minfeng Liu; Mingming Yin; Cheng Pan; Hao Li; Bomin Guo; Qingchao Zhu; Qing Wei; Mary-Pat Moyer; Ping Wang; Sanjun Cai; Ajay Goel; Huanlong Qin; Yanlei Ma
Journal:  Gastroenterology       Date:  2016-11-19       Impact factor: 22.682

4.  The association of uterine cervical microbiota with an increased risk for cervical intraepithelial neoplasia in Korea.

Authors:  H Y Oh; B-S Kim; S-S Seo; J-S Kong; J-K Lee; S-Y Park; K-M Hong; H-K Kim; M K Kim
Journal:  Clin Microbiol Infect       Date:  2015-03-06       Impact factor: 8.067

5.  A framework for human microbiome research.

Authors: 
Journal:  Nature       Date:  2012-06-13       Impact factor: 49.962

6.  Metagenomic biomarker discovery and explanation.

Authors:  Nicola Segata; Jacques Izard; Levi Waldron; Dirk Gevers; Larisa Miropolsky; Wendy S Garrett; Curtis Huttenhower
Journal:  Genome Biol       Date:  2011-06-24       Impact factor: 13.583

7.  Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling.

Authors:  Zehra Esra Ilhan; Paweł Łaniewski; Natalie Thomas; Denise J Roe; Dana M Chase; Melissa M Herbst-Kralovetz
Journal:  EBioMedicine       Date:  2019-04-24       Impact factor: 8.143

8.  Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response.

Authors:  Rezaul Karim; Bart Tummers; Craig Meyers; Jennifer L Biryukov; Samina Alam; Claude Backendorf; Veena Jha; Rienk Offringa; Gert-Jan B van Ommen; Cornelis J M Melief; Daniele Guardavaccaro; Judith M Boer; Sjoerd H van der Burg
Journal:  PLoS Pathog       Date:  2013-05-23       Impact factor: 6.823

Review 9.  Cervical Cancer in Botswana: Current State and Future Steps for Screening and Treatment Programs.

Authors:  Surbhi Grover; Mmakgomo Raesima; Memory Bvochora-Nsingo; Sebathu P Chiyapo; Dawn Balang; Neo Tapela; Onyinye Balogun; Mukendi K A Kayembe; Anthony H Russell; Barati Monare; Senate Tanyala; Jailakshmi Bhat; Kealeboga Thipe; Metlha Nchunga; Susan Mayisela; Balladiah Kizito; Ari Ho-Foster; Babe Eunice Gaolebale; Ponatshego A Gaolebale; Jason A Efstathiou; Scott Dryden-Peterson; Nicola Zetola; Stephen M Hahn; Erle S Robertson; Lilie L Lin; Chelsea Morroni; Doreen Ramogola-Masire
Journal:  Front Oncol       Date:  2015-11-03       Impact factor: 6.244

Review 10.  How the Cervical Microbiota Contributes to Cervical Cancer Risk in Sub-Saharan Africa.

Authors:  Cameron Klein; Crispin Kahesa; Julius Mwaiselage; John T West; Charles Wood; Peter C Angeletti
Journal:  Front Cell Infect Microbiol       Date:  2020-02-12       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.